Melatonin, a prognostic marker in oncologic pathology

Gineco.ro

Volumn 5, Issue 1, 2009, Pages 48-52

  Mihu, D ^a   Costin, N ^a   Ciortea, Rǎzvan ^a   Georgescu, Carmen ^a   Ciortea, Viorela Mihaela ^a   Groza, Daria Maria ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiogenesis; Apoptosis; Cancer; Melatonin; Oncostatic effect

Indexed keywords

ENDOTHELIN 1; GLUTATHIONE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LINOLEIC ACID; MELATONIN; MELATONIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CIRCADIAN RHYTHM; COLORECTAL CANCER; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; IMMUNOMODULATION; IONIZING RADIATION; KIDNEY TUMOR; LIPID PEROXIDATION; LIVER TUMOR; LUNG TUMOR; MELANOMA; METASTASIS; OVARY CARCINOMA; OXIDATIVE STRESS; PROGNOSIS; PROSTATE CANCER; RADIATION PROTECTION; SLEEP WAKING CYCLE;

EID: 79955831981     PISSN: 18414435     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Brown E.N., Choe Y., Shanahan T.L. et al: A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol. 1997; 272:506-516.
2. Claustrat B., Brun J., Chazot G.: The basic physiology and pathophysiology of melatonin. Sleep Med Rev.2005;9:11-24. (Pubitemid 40092915)
3. Kivela A, Kauppila A, Ylostao P, et al: Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women. Acta Physiol Scand.1998; 132:321-327.
4. Finocchiaro L., Callebert J., Launay J.M., et al: Melatonin biosynthesis in Drosophila: Its nature and its effects. J Neurochem.1998; 50:382-387.
5. Vakkuri O.: Diurnal rhythm of melatonin in human saliva. Acta Physiol Scand. 1985;124:409-412.
6. Kivela K., Kauppila A., Leppaluoto J., et al: Serum and amniotic fluid melatonin during human labor. J Clin Endocrinol Metab.1989;69:1065-1068. (Pubitemid 19261840)
7. Rivkees S.A.: Developing circadian rhythmicity: Basic and clinical aspects. Pediatr Clin North Am.1997; 44:467-487.
8. Kennaway D.J., Stamp G.E., Goble F.C.: Development of melatoninproduction in infants and the impact of prematurity. J Clin Endocrinol Metab.1992; 75:367-369.
9. Venkataramanujan S., Warren D., Seithikurippu R., Pandi P., Trakht I.,Cardinali D.P.:Therapeutic Actions of Melatonin in Cancer: Possible Mechanisms Integrative Cancer Therapies.2008;7(3): 189-203.
10. Sedgwick M.P. Disorders of the sleep-wake cycle in adults Postgrad Med J.1998;74:134-138.
11. Klaunig J.E., Xu Y., Isenberg J.S., et al.: The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect.1998;106(suppl 1):289-295.
12. Burdon R.H.: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med.1995;18:775-794.
13. Vijayalaxmi, Reiter R.J., Tan D.X., Herman T.S., Thomas C.R Jr.:Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys. 2004;59:639-653. (Pubitemid 38748729)
14. Reiter R.J., Tan D.X., Terron M.P., Flores L.J., Czarnocki Z.:Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol. 2007;54:1-9. (Pubitemid 46481811)
15. Vijayalaxmi, Thomas C.R Jr, Reiter R.J., Herman T.S.: Melatonin:from basic research to cancer treatment clinics. J Clin Oncol. 2002;20:2575-2601. (Pubitemid 34525746)
16. Dai M., Cui P., Yu M., Han J, Li H, Xiu R.:Melatonin modulates the expression of VEGF and FHF-1 alpha induced by CoCl2 in cultured cancer cells.J Pineal Res.2008; 44(2):121-6.
17. Kilic E., Kilic U., Reiter R.J., Bassetti C.L., Hermann D.M.: Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1.J Pineal Res. 2004;37:247-251.
18. Cui P., Luo Z., Zhang H., Su Y., Li A., Li H., Zhang J., Yang Z., Xiu R.:Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells.J Pineal Res. 2006;41(4):358-62.
19. Yu Q., Miller S.C., Osmond D.G.: Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow. J Pineal Res. 2000;29:86-93.
20. Cos S., Mediavilla M.D., Fernández R., González- Lamuño D.,Sánchez-Barcheló E.: Does melatonin induce apoptosis inMCF-7 human breast cancer cells in vitro? J Pineal Res.2002;32:90-96.
21. Rella W., Lapin V.: Immunocompetence of pinealectomized and simultaneously pinealectomized and thymectomized rats. Oncology. 1998; 333-6.
22. Reiter R.J., Cairo J.R., Karbownik M., Qi W., Tan D.X.: Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci. 2000;917:376-386.
23. Champney T.H., Mc Murray D.N.: Spleen morphology and lymphoproliferative activity in short photoperiod exposed hamsters, Plenum, 1991; pp 219-225.
24. Martins E. Jr, Fernandes L.C., Bartol I., Cipolla-Neto J., CostaRosa L.F.: The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function J Neuroimmunol. 1998;82:81-89.
25. Poon A.M., Liu Z.M., Pang C.S., Brown G.M., Pang S.F.: Evidence for a direct action of melatonin on the immune system. Biol Signals. 1994;3:107-117.
26. Davis S., Mirick D.K., Stevens R.G.: Night shift work light at night, and risk of breast cancer.J Natl Cancer Inst 2001;93:1557-62.
27. Hansen J.: Light at night, shiftwork and breastcancer risk. J Natl Cancer Inst 2001;93:513-5.
28. Skene D.J., Lockley S.W., Arendt J.: Melatonin in circadian sleep disorders in the blind. Biol Signals Recept.1999; 8:90-95. (Pubitemid 29132389)
29. Stevens R.G., Rea M.S.: Light in the built environment potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 2001;12:279-287. (Pubitemid 32515375)
30. Blask D.E., Dauchy R.T., Sauer L.A., Krause J.A., Brainard G.C.:Growth and fatty acid metabolism of human breast cancer(MCF-7) xenografts in nude rats: impact of constant light induced nocturnal melatonin suppression. Breast Cancer Res Treat. 2003;79:313-320. (Pubitemid 36750938)
31. Cos S., Blask D.E., Lemus-Wilson A., Hill SM.: Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture. J Pineal Res 1991;10:36-42.
32. Kiefer T., Ram P.T., Yuan L., Hill S.M.: Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat. 2002;71:37-45.
33. Cos S., Martinez-Campa C., Mediavilla M.D., Sánchez-Barceló E.J. : Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005;38:136-142. (Pubitemid 40293239)
34. Karasek M., Kowalski A.J., Zylinska K. Serum melatonin circadian profile in women suffering from the genital tract cancers.Neuro Endocrinol Lett. 2000;21(2):109-113.
35. Grin W., Grünberger W.A.: Significant correlation between melatonin deficiency and endometrial cancer.Gynecol Obstet Invest 1998;45(1):62-5.
36. Kanishi Y., Kobayashi Y., Noda S., Ishizuka B., Saito K: Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines.J Pineal Res.2000;28(4):227-33.
37. Gerdin M.J.,Masana M.I.,Dubocovich M.L.:Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells. Biochem Pharmacol.2004;67(11):2023-30.
38. Bartsch H, Buchberger A, Franz H, et al. Effect of melatoninand pineal extracts on human ovarian and mammary tumorcells in a chemosensitivity assay. Life Sci. 2000;67:2953-2960.
39. Bartsch C, Bartsch R Mecke D. Analysis of melatonin in patients with cancer of the reproductive system. In: Bartsch C, Bartsch H, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy; 2001:153-176.
40. Moore CB, Slopes TD. Spontaneous ovarian adenocarcinoma in the domestic turkey breeder hen (Meleagris gallopavo): effects of photoperiod and melatonin Neuro Endocrinol Lett. 2004;25(1-2):94-101.
41. Treeck O, Haldar C, Ortmann O. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep. 2006;15(1):231-5.
42. Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesisToxicology. 2006;228(2-3):333-43.
43. Shiu S.Y, Law I.C., Lau K.W., Tam P.C., Yip A.W.:Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003;35(3):177-82. (Pubitemid 37100395)
44. Blask D.E., Dauchy R.T., Sauer L.A., Krause J.A., Brainard G.C.:Light during darkness, melatonin suppression and cancer progression.Neuro Endocrinol Lett. 2002;23 Suppl 2:52-6. Review.
45. Souza A.V., Visconti M.A., Castrucci A.M.: Melatonin biological activity and binding sites in human melanoma cells. J PinealRes. 2003;34:242-248.
46. Hu D.N., McCormick S.A, Roberts JE. Effects of melatonin, its precursors and derivatives on the growth of cultured human uveal melanoma cells. Melanoma Res. 1998;8:205-210. (Pubitemid 28313757)